Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IART logo IART
Upturn stock ratingUpturn stock rating
IART logo

Integra LifeSciences Holdings (IART)

Upturn stock ratingUpturn stock rating
$13.17
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/10/2025: IART (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

12 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $16.12

1 Year Target Price $16.12

Analysts Price Target For last 52 week
$16.12 Target price
52w Low $11.06
Current$13.17
52w High $32.66

Analysis of Past Performance

Type Stock
Historic Profit -62%
Avg. Invested days 21
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/10/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.01B USD
Price to earnings Ratio -
1Y Target Price 16.12
Price to earnings Ratio -
1Y Target Price 16.12
Volume (30-day avg) 12
Beta 1.17
52 Weeks Range 11.06 - 32.66
Updated Date 07/10/2025
52 Weeks Range 11.06 - 32.66
Updated Date 07/10/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.38

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -1.78%
Operating Margin (TTM) 8.23%

Management Effectiveness

Return on Assets (TTM) 2.66%
Return on Equity (TTM) -1.86%

Valuation

Trailing PE -
Forward PE 5.83
Enterprise Value 2759787175
Price to Sales(TTM) 0.62
Enterprise Value 2759787175
Price to Sales(TTM) 0.62
Enterprise Value to Revenue 1.7
Enterprise Value to EBITDA 15.31
Shares Outstanding 77712304
Shares Floating 61777372
Shares Outstanding 77712304
Shares Floating 61777372
Percent Insiders 14.22
Percent Institutions 96.47

ai summary icon Upturn AI SWOT

Integra LifeSciences Holdings

stock logo

Company Overview

overview logo History and Background

Integra LifeSciences Holdings was founded in 1989. It has grown through acquisitions and organic development to become a leading provider of regenerative medicine products and surgical instruments.

business area logo Core Business Areas

  • Codman Specialty Surgical (CSS): Focuses on neurosurgery, dural repair, and advanced energy products.
  • Tissue Technologies: Deals with skin and wound reconstruction, tendon repair, and nerve repair products.

leadership logo Leadership and Structure

Jan De Witte serves as the President and CEO. The company has a typical corporate structure with functional departments reporting to the CEO.

Top Products and Market Share

overview logo Key Offerings

  • DuraGen: A dural regeneration matrix used in neurosurgery. Market share is significant in dural repair. Competitors include Baxter and Medtronic.
  • Integra Bilayer Matrix Wound Dressing: Used for wound healing and skin reconstruction. Competitors include Smith & Nephew and Molnlycke.

Market Dynamics

industry overview logo Industry Overview

The regenerative medicine and surgical instrument market is growing due to an aging population and increasing demand for advanced medical technologies.

Positioning

Integra LifeSciences Holdings is a key player in the regenerative medicine and neurosurgery segments, known for its innovative products and strong market presence.

Total Addressable Market (TAM)

The TAM for Integra's segments is estimated to be over $10 billion. Integra is positioned to capture a significant share of this market through product innovation and strategic acquisitions.

Upturn SWOT Analysis

Strengths

  • Strong Brand Recognition
  • Diverse Product Portfolio
  • Established Distribution Network
  • Focus on Innovation

Weaknesses

  • High Debt Levels
  • Dependence on Acquisitions
  • Integration Challenges
  • Exposure to Regulatory Risks

Opportunities

  • Expanding into Emerging Markets
  • Developing New Products
  • Acquiring Complementary Businesses
  • Increasing Adoption of Regenerative Medicine

Threats

  • Intense Competition
  • Pricing Pressures
  • Product Liability Claims
  • Economic Downturns

Competitors and Market Share

competitor logo Key Competitors

  • Medtronic (MDT)
  • Stryker (SYK)
  • Johnson & Johnson (JNJ)

Competitive Landscape

Integra LifeSciences Holdings faces stiff competition from larger medical device companies. Its competitive advantage lies in its specialized product portfolio and strong brand reputation.

Major Acquisitions

Acquired Amnio Technology Group

  • Year: 2021
  • Acquisition Price (USD millions): 14
  • Strategic Rationale: Expanded portfolio of advanced wound care products

Acquired Acell, Inc.

  • Year: 2017
  • Acquisition Price (USD millions): 300
  • Strategic Rationale: Accelerated growth in advanced wound care.

Growth Trajectory and Initiatives

Historical Growth: Integra LifeSciences Holdings has grown through a combination of organic growth and acquisitions.

Future Projections: Analysts project moderate revenue growth and improved profitability for Integra LifeSciences Holdings in the coming years.

Recent Initiatives: Integra LifeSciences Holdings is focused on expanding its product portfolio through R&D and strategic acquisitions.

Summary

Integra LifeSciences Holdings has a strong position in regenerative medicine and surgical instruments but faces financial challenges, including high debt and negative net income. The company's strengths lie in its product portfolio and innovation, while it needs to address profitability and cash flow. Future growth depends on successful product development and acquisitions. Regulatory changes and increasing competition need to be monitored.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Integra LifeSciences Holdings

Exchange NASDAQ
Headquaters Princeton, NJ, United States
IPO Launch date 1995-08-16
President, CEO & Director Ms. Mojdeh Poul
Sector Healthcare
Industry Medical Devices
Full time employees 4396
Full time employees 4396

Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.